Browse by UCL people
Group by: Type | Date
Number of items: 97.
Article
Ahmed, F;
Ings, SJ;
Pizzey, AR;
Blundell, MP;
Thrasher, AJ;
Ye, HT;
Fahey, A;
... Yong, KL; + view all
(2004)
Impaired bone marrow homing of cytokine-activated CD34<sup>+</sup> cells in the NOD/SCID model.
Blood
, 103
(6)
pp. 2079-2087.
10.1182/blood-2003-06-1770.
|
 |
|
Ahmedzai, SH;
Snowden, JA;
Ashcroft, AJ;
Cairns, DA;
Williams, C;
Hockaday, A;
Cavenagh, JD;
... Cook, G; + view all
(2019)
Patient-Reported Outcome Results From the Open-Label, Randomized Phase III Myeloma X Trial Evaluating Salvage Autologous Stem-Cell Transplantation in Relapsed Multiple Myeloma.
Journal of Clinical Oncology
, 37
(19)
pp. 1617-1628.
10.1200/jco.18.01006.
|
 |
|
Ainley, L;
Chavda, SJ;
Counsell, N;
Cheesman, S;
Newrick, F;
Horder, J;
Kyriakou, C;
... Yong, K; + view all
(2021)
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation.
British Journal of Haematology
, 192
(3)
e73-e77.
10.1111/bjh.17248.
|
|
Alrasheed, N;
Lee, L;
Ghorani, E;
Henry, JY;
Conde, L;
Chin, M;
Galas-Filipowicz, D;
... Yong, KL; + view all
(2020)
Marrow-Infiltrating Regulatory T Cells Correlate with the Presence of Dysfunctional CD4⁺PD-1⁺ Cells and Inferior Survival in Patients with Newly Diagnosed Multiple Myeloma.
Clinical Cancer Research
, 26
(13)
pp. 3443-3454.
10.1158/1078-0432.CCR-19-1714.
|
|
Atkin, C;
Iqbal, G;
Planche, T;
Pratt, G;
Yong, K;
Wood, J;
Raynes, K;
... Trial Investigators; + view all
(2020)
Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial.
British Journal of Haematology
10.1111/bjh.17044.
(In press).
|
|
|
Auner, HW;
Yong, KL;
(2018)
More convenient proteasome inhibition for improved outcomes.
Lancet Oncology
, 19
(7)
pp. 856-858.
10.1016/S1470-2045(18)30411-X.
|
|
|
Bowcock, Stella;
Atkin, Catherine;
Iqbal, Gulnaz;
Pratt, Guy;
Yong, Kwee;
Neal, Richard D;
Planche, Tim;
... Drayson, Mark T; + view all
(2023)
Presenting Symptoms in Newly Diagnosed Myeloma, Relation to Organ Damage, and Implications for Symptom-Directed Screening: A Secondary Analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) Trial.
Cancers
, 15
(13)
, Article 3337. 10.3390/cancers15133337.
|
|
|
Brown, S;
Hinsley, S;
Ballesteros, M;
Bourne, S;
McGarry, P;
Sherratt, D;
Flanagan, L;
... Myeloma UK Clinical Trials Network, .; + view all
(2016)
The MUK five protocol: a phase II randomised, controlled, parallel group, multi-centre trial of carfilzomib, cyclophosphamide and dexamethasone (CCD) vs. cyclophosphamide, bortezomib (Velcade) and dexamethasone (CVD) for first relapse and primary refractory multiple myeloma.
BMC Hematology
, 16
, Article 14. 10.1186/s12878-016-0053-9.
|
|
Bustoros, Mark;
Anand, Shankara;
Sklavenitis-Pistofidis, Romanos;
Redd, Robert;
Boyle, Eileen M;
Zhitomirsky, Benny;
Dunford, Andrew J;
... Ghobrial, Irene M; + view all
(2022)
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes.
Nature Communications
, 13
, Article 3449. 10.1038/s41467-022-30694-w.
|
|
Bustoros, M;
Sklavenitis-Pistofidis, R;
Park, J;
Redd, R;
Zhitomirsky, B;
Dunford, AJ;
Salem, K;
... Ghobrial, IM; + view all
(2020)
Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
Journal of Clinical Oncology
, 38
(21)
pp. 2380-2389.
10.1200/JCO.20.00437.
|
|
Camilleri, M;
Sive, J;
Wilson, W;
Pang, G;
Jenner, R;
Phillips, E;
Popat, R;
... Yong, K; + view all
(2021)
COVID-19 and myeloma clinical research - experience from the CARDAMON clinical trial.
British Journal of Haematology
, 192
(1)
E14-E16.
10.1111/bjh.17168.
|
|
Camilleri, M;
Cuadrado, M;
Phillips, E;
Wilson, W;
Jenner, R;
Pang, G;
Kamora, S;
... Yong, K; + view all
(2021)
Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
British Journal of Haematology
10.1111/bjh.17377.
(In press).
|
|
|
Cavenagh, J;
Oakervee, H;
Baetiong-Caguioa, P;
Davies, F;
Gharibo, M;
Rabin, N;
Kurman, M;
... Yong, K; + view all
(2017)
A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
British Journal of Cancer
, 117
(9)
pp. 1295-1302.
10.1038/bjc.2017.302.
|
|
|
Chakrabarti, S.;
Mackinnon, S.;
Chopra, R.;
Kottaridis, P.D.;
Peggs, K.;
O'Gorman, P.;
Chakraverty, R.;
... Milligan, D.W.; + view all
(2002)
High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.
Blood
, 99
(12)
pp. 4357-4363.
10.1182/blood.V99.12.4357.
|
|
|
Chan, WY;
Counsell, N;
de Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, J;
Adedayo, T;
... Yong, KL; + view all
(2022)
Outcomes of relapse in patients with deferred autologous stem cell transplant after achieving at least very good partial response following bortezomib, adriamycin, dexamethasone chemotherapy for newly diagnosed multiple myeloma in the phase II PADIMAC trial.
British Journal of Haematology
, 196
(4)
e33-e37.
10.1111/bjh.17903.
|
|
Chapman, MA;
Sive, J;
Ambrose, J;
Roddie, C;
Counsell, N;
Lach, A;
Abbasian, M;
... Yong, K; + view all
(2018)
RNA-Seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib/lenalidomide decision signature.
Blood
, 132
(20)
pp. 2154-2165.
10.1182/blood-2018-05-849893.
|
|
Chari, A;
Samur, MK;
Martinez-Lopez, J;
Cook, G;
Biran, N;
Yong, KL;
Hungria, VTDM;
... Avet-Loiseau, H; + view all
(2020)
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
Blood
, 136
(26)
pp. 3033-3040.
10.1182/blood.2020008150.
|
|
Chavda, SJ;
Maciocia, PM;
Mesiri, P;
Counsell, N;
Kothari, J;
Bird, A;
Mariner, C;
... Yong, K; + view all
(2019)
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
British Journal of Haematology
, 185
(2)
pp. 350-353.
10.1111/bjh.15487.
|
|
Chavda, SJ;
Pocock, R;
Cheesman, S;
Lee, K-M;
Dowling, E;
Marks, DJB;
Kyriakou, C;
... Popat, R; + view all
(2020)
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendations.
British Journal of Haematology
10.1111/bjh.16889.
(In press).
|
|
|
Chicca, IJ;
Heaney, JLJ;
Iqbal, G;
Dunn, JA;
Bowcock, S;
Planche, T;
Pratt, G;
... Drayson, MT; + view all
(2020)
Stratifying risk of infection and response to therapy in patients with myeloma: a prognostic study.
Efficacy and Mechanism Evaluation
, 7
(10)
10.3310/eme07100.
|
|
|
Chicca, IJ;
Heaney, JLJ;
Iqbal, G;
Dunn, JA;
Bowcock, S;
Pratt, G;
Yong, KL;
... Drayson, MT; + view all
(2020)
Anti-bacterial antibodies in multiple myeloma patients at disease presentation, in response to therapy and in remission: implications for patient management.
Blood Cancer Journal
, 10
(11)
, Article 114. 10.1038/s41408-020-00370-7.
|
|
|
Chin, M;
Sive, JI;
Allen, C;
Roddie, C;
Chavda, SJ;
Smith, D;
Blombery, P;
... Yong, KL; + view all
(2017)
Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival.
Blood Cancer Journal
, 7
, Article e610. 10.1038/bcj.2017.76.
|
|
|
Cohen, OC;
Brodermann, MH;
Blakeney, IJ;
Mahmood, S;
Sachchithanantham, S;
Ravichandran, S;
Law, S;
... Wechalekar, AD; + view all
(2020)
Rapid response to single agent daratumumab is associated with improved progression-free survival in relapsed/refractory AL amyloidosis.
Amyloid
, 27
(3)
pp. 200-205.
10.1080/13506129.2020.1765768.
|
|
Cohen, OC;
Counsell, N;
Rabin, N;
Popat, R;
Owen, RG;
Popova, B;
Schofield, O;
... Yong, KL; + view all
(2019)
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
[Letter].
British Journal of Haematology
, 185
(5)
pp. 948-951.
10.1111/bjh.15649.
|
|
Cohen, OC;
Sharpley, F;
Gillmore, JD;
Lachmann, HJ;
Sachchithanantham, S;
Mahmood, S;
Fontana, M;
... Wechalekar, AD; + view all
(2020)
Use of ixazomib, lenalidomide and dexamethasone in patients with relapsed amyloid light‐chain amyloidosis.
British Journal of Haematology
, 189
(4)
pp. 643-649.
10.1111/bjh.16401.
|
|
Cook, G;
Ashcroft, AJ;
Cairns, DA;
Williams, CD;
Brown, JM;
Cavenagh, JD;
Snowden, JA;
... National Cancer Research Institute Haemato-oncology Clinical Stu, .; + view all
(2016)
The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
Lancet Haematology
, 3
(7)
e340-e351.
10.1016/S2352-3026(16)30049-7.
|
|
|
Cook, G;
Royle, K-L;
O'Connor, S;
Cairns, DA;
Ashcroft, AJ;
Williams, CD;
Hockaday, A;
... National Cancer Research Institute Haemato-oncology Clinical Stu; + view all
(2019)
The impact of cytogenetics on duration of response and overall survival in patients with relapsed multiple myeloma (long-term follow-up results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial.
British Journal of Haematology
10.1111/bjh.15782.
(In press).
|
|
|
Dimopoulos, MA;
Leleu, X;
Moreau, P;
Richardson, PG;
Liberati, AM;
Harrison, SJ;
Miles Prince, H;
... Yong, K; + view all
(2020)
Isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma patients with renal impairment: ICARIA-MM subgroup analysis.
Leukemia
10.1038/s41375-020-0868-z.
(In press).
|
|
Drayson, MT;
Bowcock, S;
Planche, T;
Iqbal, G;
Pratt, G;
Yong, K;
Wood, J;
... Dunn, JA; + view all
(2019)
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial.
The Lancet Oncology
, 20
(12)
pp. 1760-1772.
10.1016/S1470-2045(19)30506-6.
|
|
|
Drayson, MT;
Bowcock, S;
Planche, T;
Iqbal, G;
Pratt, G;
Yong, K;
Wood, J;
... Dunn, JA; + view all
(2019)
Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT.
Health Technology Assessment
, 23
(62)
10.3310/hta23620.
|
|
|
El-Sharkawi, D;
Ng, C-H;
Payne, EMC;
Yong, KL;
Ardeshna, KM;
Khwaja, A;
Townsend, W;
(2019)
Clinical outcomes and survival of patients with myeloma and lymphoma enrolled into phase I clinical trials.
British Journal of Haematology
, 185
(2)
pp. 344-347.
10.1111/bjh.15457.
|
|
Engelhardt, M;
Yong, K;
Bringhen, S;
Waesch, R;
(2019)
Carfilzomib combination treatment as first-line therapy in multiple myeloma: where do we go from the Carthadex (KTd)-trial update?
[Editorial comment].
Haematologica
, 104
(11)
pp. 2128-2131.
10.3324/haematol.2019.228684.
|
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, JW;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Response to 'Impact of immunosuppression on mortality in critically ill COVID-19 patients'.
British Journal of Haematology
, 191
(3)
pp. 505-506.
10.1111/bjh.17110.
|
|
Fox, TA;
Troy-Barnes, E;
Kirkwood, AA;
Chan, WY;
Day, J;
Chavda, SJ;
Kumar, EA;
... Ardeshna, KM; + view all
(2020)
Clinical outcomes and risk factors for severe COVID‐19 infection in patients with haematological disorders receiving chemo‐ or immunotherapy.
British Journal of Haematology
, 191
(2)
pp. 194-206.
10.1111/bjh.17027.
|
|
Gonzalez-McQuire, S;
Yong, K;
Leleu, H;
Mennini, FS;
Flinois, A;
Gazzola, C;
Schoen, P;
... Fink, L; + view all
(2018)
Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
Journal of Medical Economics
, 21
(5)
pp. 450-467.
10.1080/13696998.2017.1421546.
|
|
Gooding, Sarah;
Ansari-Pour, Naser;
Kazeroun, Mohammad H;
Karagoz, Kubra;
Polonskaia, Ann;
Angulo Salazar, Mirian;
Fitzsimons, Evelyn;
... Thakurta, Anjan; + view all
(2022)
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Blood
, 140
(16)
pp. 1816-1821.
10.1182/blood.2022015909.
|
|
Groeneveldt, L;
Mein, G;
Garrod, R;
Jewell, AP;
Van Someren, K;
Stephens, R;
D'Sa, SP;
(2013)
A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors.
BMC Cancer
, 13
, Article 31. 10.1186/1471-2407-13-31.
|
|
|
Hagos, Yeman B;
Lecat, Catherine SY;
Patel, Dominic;
Mikolajczak, Anna;
Castillo, Simon P;
Lyon, Emma J;
Foster, Kane;
... Yuan, Yinyin; + view all
(2023)
Deep learning enables spatial mapping of the mosaic microenvironment of myeloma bone marrow trephine biopsies.
Cancer Research
10.1158/0008-5472.can-22-2654.
|
|
|
Hájek, R;
Masszi, T;
Petrucci, MT;
Palumbo, A;
Rosiñol, L;
Nagler, A;
Yong, KL;
... Ludwig, H; + view all
(2016)
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS).
Leukemia
, 31
(1)
pp. 107-114.
10.1038/leu.2016.176.
|
|
|
Harrison, SJ;
Perrot, A;
Alegre, A;
Simpson, D;
Wang, MC;
Spencer, A;
Delimpasi, S;
... Richardson, P; + view all
(2021)
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
British Journal of Haematology
10.1111/bjh.17499.
(In press).
|
|
|
Heinrich, M;
Fisher, A;
Paton, B;
McCourt, O;
Beeken, RJ;
Hackshaw, A;
Wardle, J;
(2016)
Lifestyle in Multiple Myeloma - a longitudinal cohort study protocol.
BMC Cancer
, 16
, Article 387. 10.1186/s12885-016-2407-x.
|
|
|
Keddie, S;
Foldes, D;
Caimari, F;
Baldeweg, SE;
Bomsztyk, J;
Ziff, OJ;
Fehmi, J;
... Lunn, MP; + view all
(2020)
Clinical characteristics, risk factors, and outcomes of POEMS syndrome: A longitudinal cohort study.
Neurology
, 95
(3)
e268-e279.
10.1212/WNL.0000000000009940.
|
|
Khwaja, Jahanzaib;
Bomsztyk, Joshua;
Mahmood, Shameem;
Wisniowski, Brendan;
Shah, Raakhee;
Tailor, Anish;
Yong, Kwee;
... Wechalekar, Ashutosh D; + view all
(2022)
High response rates with single-agent belantamab mafodotin in relapsed systemic AL amyloidosis.
Blood Cancer Journal
, 12
(9)
, Article 128. 10.1038/s41408-022-00717-2.
|
|
Kolovos, S;
Nador, G;
Kishore, B;
Streetly, M;
Rabin, NK;
Chantry, AD;
Yong, K;
... Pinedo-Villanueva, R; + view all
(2019)
Unplanned admissions for patients with myeloma in the UK: Low frequency but high costs.
Journal of Bone Oncology
, 17
, Article 100243. 10.1016/j.jbo.2019.100243.
|
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Koutoukidis, DA;
Land, J;
Hackshaw, A;
Heinrich, M;
McCourt, O;
Beeken, RJ;
Philpott, S;
... Yong, KL; + view all
(2020)
Fatigue, quality of life and physical fitness following an exercise intervention in multiple myeloma survivors (MASCOT): an exploratory randomised Phase 2 trial utilising a modified Zelen design.
British Journal of Cancer
10.1038/s41416-020-0866-y.
(In press).
|
|
|
Land, J;
McCourt, O;
Heinrich, M;
Beeken, RJ;
Koutoukidis, DA;
Paton, B;
Yong, K;
... Fisher, A; + view all
(2020)
The adapted Zelen was a feasible design to trial exercise in myeloma survivors.
Journal of Clinical Epidemiology
, 125
pp. 76-83.
10.1016/j.jclinepi.2020.04.004.
|
|
|
Latifoltojar, A;
Hall-Craggs, M;
Bainbridge, A;
Rabin, N;
Popat, R;
Rismani, A;
D'Sa, S;
... Punwani, S; + view all
(2017)
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib induction.
European Radiology
10.1007/s00330-017-4907-8.
(In press).
|
|
|
Latifoltojar, A;
Hall-Craggs, M;
Rabin, N;
Popat, R;
Bainbridge, A;
Dikaios, N;
Sokolska, M;
... Yong, K; + view all
(2017)
Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.
British Journal of Haematology
, 176
(2)
pp. 222-233.
10.1111/bjh.14401.
|
|
Lecat, Catherine;
Boyle, Eileen M;
Hughes, Daniel;
Lee, Lydia;
Smith, Dean;
Bygrave, Ceri;
Ramasamy, Karthik;
(2024)
Challenges in designing and running smouldering myeloma interventional clinical trials.
eJHaem
10.1002/jha2.880.
(In press).
|
|
Lecat, CSY;
McCourt, O;
Land, J;
Yong, K;
Fisher, A;
(2021)
Multiple myeloma and physical activity.
BMC Research Notes
, 14
(1)
, Article 171. 10.1186/s13104-021-05591-y.
|
|
|
Lecat, CSY;
Taube, JBB;
Wilson, W;
Carmichael, J;
Parrish, C;
Wallis, G;
Kyriakou, C;
... Popat, R; + view all
(2021)
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple Myeloma.
Frontiers in Oncology
, 11
, Article 703233. 10.3389/fonc.2021.703233.
|
|
|
Lee, L;
Alrasheed, N;
Khandelwal, G;
Fitzsimons, E;
Richards, H;
Wilson, W;
Chavda, SJ;
... Yong, K; + view all
(2021)
Increased Immune-Regulatory Receptor Expression on Effector T Cells as Early Indicators of Relapse Following Autologous Stem Cell Transplantation for Multiple Myeloma.
Frontiers Immunology
, 12
, Article 618610. 10.3389/fimmu.2021.618610.
|
|
|
Lee, L;
Draper, B;
Chaplin, N;
Philip, B;
Chin, M;
Galas-Filipowicz, D;
Onuoha, S;
... Pule, M; + view all
(2017)
An APRIL based chimeric antigen receptor for dual targeting of BCMA and TACI in Multiple Myeloma.
Blood
, 2017
(5)
, Article 781351. 10.1182/blood-2017-05-781351.
|
|
Leng, H;
Zhang, H;
Li, L;
Zhang, S;
Wang, Y;
Chavda, SJ;
Galas-Filipowicz, D;
... Horwood, NJ; + view all
(2022)
Modulating glycosphingolipid metabolism and autophagy improves outcomes in pre-clinical models of myeloma bone disease.
Nature Communications
, 13
(1)
, Article 7868. 10.1038/s41467-022-35358-3.
|
|
Maciocia, N;
Melville, A;
Cheesman, S;
Sharpley, F;
Ramasamy, K;
Streetly, M;
Jenner, M;
... Rabin, N; + view all
(2017)
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience.
British Journal of Haematology
, 176
(6)
pp. 908-917.
10.1111/bjh.14547.
|
|
|
Maciocia, N;
Wechalekar, A;
Yong, K;
(2016)
Monoclonal gammopathy of undetermined significance and smoldering myeloma (SMM): a practical guide to management.
Hematological Oncology
, 35
(4)
pp. 432-439.
10.1002/hon.2345.
|
|
|
Malhotra, K;
Butler, JS;
Yu, HM;
Selvadurai, S;
D'Sa, S;
Rabin, N;
Kyriakou, C;
... Molloy, S; + view all
(2016)
Spinal disease in myeloma: cohort analysis at a specialist spinal surgery centre indicates benefit of early surgical augmentation or bracing.
BMC Cancer
, 16
, Article 444. 10.1186/s12885-016-2495-7.
|
|
|
Manwani, R;
Hegenbart, U;
Mahmood, S;
Sachchithanantham, S;
Kyriakou, C;
Yong, K;
Popat, R;
... Wechalekar, A; + view all
(2018)
Deferred autologous stem cell transplantation in systemic AL amyloidosis.
Blood Cancer Journal
, 8
, Article 101. 10.1038/s41408-018-0137-9.
|
|
|
Manwani, R;
Mahmood, S;
Sachchithanantham, S;
Lachmann, HJ;
Gillmore, JD;
Yong, K;
Rabin, N;
... Wechalekar, AD; + view all
(2019)
Carfilzomib is an effective upfront treatment in AL amyloidosis patients with peripheral and autonomic neuropathy.
British Journal of Haematology
, 187
(5)
pp. 638-641.
10.1111/bjh.16122.
|
|
Martin, Thomas;
Dimopoulos, Meletios-Athanasios;
Mikhael, Joseph;
Yong, Kwee;
Capra, Marcelo;
Facon, Thierry;
Hajek, Roman;
... Moreau, Philippe; + view all
(2023)
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.
Blood Cancer Journal
, 13
, Article 72. 10.1038/s41408-023-00797-8.
|
|
|
Mateos, M-V;
Ludwig, H;
Bazarbachi, A;
Beksac, M;
Bladé, J;
Boccadoro, M;
Cavo, M;
... Sonneveld, P; + view all
(2019)
Insights on Multiple Myeloma Treatment Strategies.
HemaSphere
, 3
(1)
, Article e163. 10.1097/HS9.0000000000000163.
|
|
|
Maybury, B;
Cook, G;
Pratt, G;
Yong, K;
Ramasamy, K;
(2016)
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma.
Biology of Blood and Marrow Transplantation
, 22
(11)
pp. 1926-1937.
10.1016/j.bbmt.2016.06.004.
|
|
|
McCourt, Orla;
Fisher, Abigail;
Ramdharry, Gita;
Land, Joanne;
Roberts, Anna L;
Rabin, Neil;
Yong, Kwee;
(2023)
Exercise prehabilitation for people with myeloma undergoing autologous stem cell transplantation: results from PERCEPT pilot randomised controlled trial.
Acta Oncologica
, 62
(7)
pp. 696-705.
10.1080/0284186X.2023.2178326.
|
|
McCourt, O;
Fisher, A;
Ramdharry, G;
Roberts, AL;
Land, J;
Rabin, N;
Yong, K;
(2020)
PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma.
BMJ Open
, 10
(1)
, Article e033176. 10.1136/bmjopen-2019-033176.
|
|
|
McCourt, O;
Yong, K;
Ramdharry, G;
Fisher, A;
(2021)
Physical Activity During and After Haematological Cancer Treatment: A Cross-Sectional Survey of Haematology Healthcare Professionals in the United Kingdom.
Journal of Multidisciplinary Healthcare
, 14
pp. 1659-1671.
10.2147/JMDH.S295888.
|
|
|
Mohty, M;
Cavo, M;
Fink, L;
Gonzalez-McQuire, S;
Leleu, H;
Mateos, M-V;
Raab, MS;
... Yong, K; + view all
(2019)
Understanding mortality in multiple myeloma: Findings of a European retrospective chart review.
European Journal of Haematology
, 103
(2)
pp. 107-115.
10.1111/ejh.13264.
|
|
|
Moreau, P;
Kumar, SK;
Miguel, JS;
Davies, F;
Zamagni, E;
Bahlis, N;
Ludwig, H;
... Richardson, PG; + view all
(2021)
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
The Lancet Oncology
, 22
(3)
E105-E118.
10.1016/S1470-2045(20)30756-7.
|
|
Moreau, P;
Dimopoulos, MA;
Yong, K;
Mikhael, J;
Risse, M-L;
Asset, G;
Martin, T;
(2020)
Isatuximab plus carfilzomib/dexamethasone versus carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma: IKEMA Phase III study design.
Future Oncology
, 16
(2)
pp. 4347-4358.
10.2217/fon-2019-0431.
|
|
|
Pihan, M;
Keddie, S;
D'Sa, S;
Church, AJ;
Yong, KL;
Reilly, MM;
Lunn, MP;
(2018)
Raised VEGF: High sensitivity and specificity in the diagnosis of POEMS syndrome.
Neurology, Neuroimmunology & Neuroinflammation
, 5
(5)
, Article e486. 10.1212/NXI.0000000000000486.
|
|
|
Popat, R;
Counsell, N;
De Tute, R;
De-Silva, D;
Phillips, EH;
Cavenagh, JD;
Adedayo, T;
... Yong, K; + view all
(2021)
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma Trial.
British Journal of Haematology
, 193
(3)
e19-e22.
10.1111/bjh.17391.
|
|
Popat, R;
Brown, SR;
Flanagan, L;
Hall, A;
Gregory, W;
Kishore, B;
Streetly, M;
... Cavenagh, J; + view all
(2019)
Extended follow‐up and the feasibility of Panobinostat maintenance for patients with Relapsed Multiple Myeloma treated with Bortezomib, Thalidomide, Dexamethasone plus Panobinostat (MUK six open label, multi‐centre phase I/II Clinical Trial).
British Journal of Haematology
, 185
(3)
pp. 573-578.
10.1111/bjh.15551.
|
|
Popat, R;
Brown, SR;
Flanagan, L;
Hall, A;
Gregory, W;
Kishore, B;
Streetly, M;
... Myeloma UK Early Phase Clinical Trial Network, .; + view all
(2016)
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
The Lancet Haematology
, 3
(12)
e572-e580.
10.1016/S2352-3026(16)30165-X.
|
|
|
Popat, R;
Warcel, D;
O'Nions, J;
Cowley, A;
Smith, S;
Tucker, WR;
Yong, K;
(2020)
Characterization of response and corneal events with extended follow-up after belantamab mafodotin (GSK2857916) monotherapy for patients with relapsed multiple myeloma: a case series from the first-time-in-human clinical trial.
Haematologica
, 105
(5)
E261-E263.
10.3324/haematol.2019.235937.
|
|
|
Raab, MS;
Cavo, M;
Delforge, M;
Driessen, C;
Fink, L;
Flinois, A;
Gonzalez-McQuire, S;
... Yong, K; + view all
(2016)
Multiple myeloma: practice patterns across Europe.
British Journal of Haematology
, 175
(1)
pp. 66-76.
10.1111/bjh.14193.
|
|
|
Raab, MS;
Fink, L;
Schoen, P;
Gonzalez-McQuire, S;
Flinois, A;
Cavo, M;
Mateos, M-V;
(2019)
Evolution of multiple myeloma treatment practices in Europe from 2014 to 2016.
British Journal of Haematology
, 185
(5)
pp. 981-984.
10.1111/bjh.15680.
|
|
Richardson, PG;
Harrison, SJ;
Bringhen, S;
Schjesvold, F;
Yong, K;
Campana, F;
Le-Guennec, S;
... Dimopoulos, MA; + view all
(2021)
Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study.
Future Oncology
, 17
(34)
pp. 4797-4812.
10.2217/fon-2021-0568.
|
|
|
Ryland, GL;
Jones, K;
Chin, M;
Markham, J;
Aydogan, E;
Kankanige, Y;
Caruso, M;
... Blombery, P; + view all
(2018)
Novel genomic findings in multiple myeloma identified through routine diagnostic sequencing.
Journal of Clinical Pathology
, 71
(10)
pp. 895-899.
10.1136/jclinpath-2018-205195.
|
|
|
San-Miguel, J;
Dhakal, B;
Yong, K;
Spencer, A;
Anguille, S;
Mateos, M-V;
Fernandez de Larrea, C;
... Einsele, H; + view all
(2023)
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.
New England Journal of Medicine
, 389
(4)
pp. 335-347.
10.1056/NEJMoa2303379.
|
|
|
Shah, V;
Sherborne, AL;
Johnson, DC;
Ellis, S;
Price, A;
Chowdhury, F;
Kendall, J;
... on behalf of NCRI Haematology Clinical Studies Group; + view all
(2020)
Predicting ultrahigh risk multiple myeloma by molecular profiling:
an analysis of newly diagnosed transplant eligible myeloma XI trial
patients.
Leukemia
10.1038/s41375-020-0750-z.
|
|
|
Smith, D;
Yong, K;
(2016)
Advances in understanding prognosis in myeloma.
British Journal of Haematology
, 175
(3)
pp. 367-380.
10.1111/bjh.14304.
|
|
Smith, L;
McCourt, O;
Heinrich, M;
Paton, B;
Yong, K;
Wardle, J;
Fisher, A;
(2015)
Multiple myeloma and physical activity: a scoping review.
BMJ Open
, 5
, Article e009576. 10.1136/bmjopen-2015-009576.
|
|
Snowden, JA;
Greenfield, DM;
Bird, JM;
Boland, E;
Bowcock, S;
Fisher, A;
Low, E;
... UK Myeloma Forum (UKMF) and the British Society for Haematology, .; + view all
(2017)
Guidelines for screening and management of late and long-term consequences of myeloma and its treatment.
British Journal of Haematology
, 176
(6)
pp. 888-907.
10.1111/bjh.14514.
|
|
Sudha, Parvathi;
Ahsan, Aarif;
Ashby, Cody;
Kausar, Tasneem;
Khera, Akhil;
Kazeroun, Mohammad;
Hsu, Chih-Chao;
... Walker, Brian A; + view all
(2022)
MGP Panel is a comprehensive targeted genomics panel for molecular profiling of multiple myeloma patients.
Clinical Cancer Research
, 28
(13)
2854-2864..
10.1158/1078-0432.CCR-21-3695.
|
|
Trudel, S;
Lendvai, N;
Popat, R;
Voorhees, PM;
Reeves, B;
Libby, EN;
Richardson, PG;
... Cohen, AD; + view all
(2018)
Targeting B-cell maturation antigen with GSK2857916 antibody-drug conjugate in relapsed or refractory multiple myeloma (BMA117159): a dose escalation and expansion phase 1 trial.
The Lancet Oncology
, 19
(12)
pp. 1641-1653.
10.1016/S1470-2045(18)30576-X.
|
|
van de Donk, NWCJ;
Pawlyn, C;
Yong, KL;
(2021)
Multiple myeloma.
The Lancet
, 397
(10272)
pp. 410-427.
10.1016/S0140-6736(21)00135-5.
|
|
Westerland, OA;
Pratt, G;
Kazmi, M;
El-Najjar, I;
Streetly, M;
Yong, K;
Morris, M;
... British Society of Haematology Imaging Practice Guidelines Worki; + view all
(2018)
National survey of imaging practice for suspected or confirmed plasma cell malignancies.
British Journal of Radiology
, 91
(1092)
10.1259/bjr.20180462.
(In press).
|
|
|
Xu, Ke;
Kaffo, Eleanor;
Baker, Robert;
Nacheva, Elisabeth;
McMillan, Annabel;
Lee, Lydia;
Papanikolaou, Xenofon;
... Gupta, Rajeev; + view all
(2024)
Myeloid neoplasm post cytotoxic treatment in patients with multiple myeloma.
eJHaem
, 5
(5)
pp. 1089-1091.
10.1002/jha2.1017.
|
|
|
Yip, HM;
Yong, K;
De-Silva, D;
Rabin, N;
(2020)
Assessing the safety of autologous stem cell transplant pathway via ambulatory care for patients with multiple myeloma.
Hematology/Oncology and Stem Cell Therapy
10.1016/j.hemonc.2020.01.001.
(In press).
|
|
|
Yong, K;
Wilson, W;
de Tute, RM;
Camilleri, M;
Ramasamy, K;
Streetly, M;
Sive, J;
... Popat, R; + view all
(2022)
Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
The Lancet Haematology
, 10
(2)
e93-e106.
10.1016/S2352-3026(22)00350-7.
|
|
Yong, KL;
Hinsley, S;
Auner, HW;
Bygrave, C;
Kaiser, MF;
Ramasamy, K;
De Tute, RM;
... Brown, SR; + view all
(2021)
Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multi-centre, phase II, randomized, controlled trial (MUKfive).
Haematologica
, 106
(10)
pp. 2694-2706.
10.3324/haematol.2021.278399.
|
|
Yong, K;
Cavet, J;
Johnson, P;
Morgan, G;
Williams, C;
Nakashima, D;
Akinaga, S;
... Cavenagh, J; + view all
(2016)
Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.
British Journal of Cancer
, 114
(1)
pp. 7-13.
10.1038/bjc.2015.422.
|
|
Yong, K;
Delforge, M;
Driessen, C;
Fink, L;
Flinois, A;
Gonzalez-McQuire, S;
Karlin, L;
... Cavo, M; + view all
(2016)
Multiple myeloma: patient outcomes in real-world practice.
British Journal of Haematology
, 175
(2)
pp. 252-264.
10.1111/bjh.14213.
|
|
|
Yong, K;
van de Donk, N;
(2019)
Oral proteasome inhibitor maintenance for multiple myeloma.
The Lancet
, 393
(10168)
pp. 204-205.
10.1016/S0140-6736(18)33128-3.
|
|
Ziff, Monica;
Lawson, Gabrielle;
De-Silva, Dunnya;
Cheesman, Simon;
Kyriakou, Charalampia;
Mahmood, Shameem;
Papanikolaou, Xenofon;
... Popat, Rakesh; + view all
(2021)
Ixazomib with lenalidomide and dexamethasone for patients with relapsed multiple myeloma: impact of 17p deletion and sensitivity to proteasome inhibitors from a real world data-set.
Leukemia & Lymphoma
, 62
(5)
pp. 1243-1246.
10.1080/10428194.2020.1864356.
|
Proceedings paper
|
Hagos, YB;
Lecat, CSY;
Patel, D;
Lee, L;
Tran, TA;
Justo, MR;
Yong, K;
(2021)
Cell abundance aware deep learning for cell detection on highly imbalanced pathological data.
In:
2021 IEEE 18th International Symposium on Biomedical Imaging (ISBI).
(pp. pp. 1438-1442).
IEEE: Nice, France.
|
|
Conference item
|
McCourt, O;
Heinrich, M;
Fisher, A;
Paton, B;
Beeken, R;
Hackshaw, A;
Rismani, A;
... Yong, K; + view all
(2016)
Use of an 'adapted Zelen' design in a randomised controlled trial of a physiotherapist-led exercise intervention in patients with myeloma.
Presented at: th European Congress of the European Region of the World Confederation of Physical Therapy (ER-WCPT), Liverpool, UK.
|
